São Paulo, May 2025 – Eurofarma, a leading pharmaceutical company in innovation and a benchmark for ESG initiatives, has just released its 2025 Annual Sustainability Report (base year 2024). The document provides a comprehensive overview of the achievements, results, and commitments consolidated by the company, serving as one of the primary channels for external communication and accountability to all of the company's stakeholders.

More than just presenting figures, the annual report transparently communicates Eurofarma's strategies, actions, and results, highlighting the "Eurofarma Way of Being" and how the organization operates to generate shared results with society in an ethical, responsible manner, connected to the future and the principle of sustainable growth.

In this edition, you can see how Eurofarma's Environmental, Social, and Governance (ESG) initiatives are advancing and contributing to a better world. The report also reinforces the role of transparency and open dialogue with all those who are part of our journey—employees, partners, customers, investors, and society as a whole.

Eurofarma's annual sustainability report is assured by KPMG independent auditing, in compliance with the Global Reporting Initiative (GRI) international standard, and also includes SASB (Sustainability Accounting Standards Board) indicators for the Biotechnology & Pharmaceuticals industries.

Click here to access the full Sustainability Report.

About Eurofarma
Founded in 1972, Eurofarma operates in the healthcare sector, producing and marketing products and services to improve people's quality of life. Focused on shared value generation, it covers key pharmaceutical segments such as prescription drugs, OTC and personal care, generics, hospital, oncology, and animal health, in addition to providing third-party manufacturing services. A leader in pharmacy sales in Latin America and in prescriptions in Brazil, it offers broad coverage across therapeutic classes, with a portfolio comprising over 4,000 SKUs (presentations) serving major medical specialties. Eurofarma is present in 24 countries, with 100% coverage in Latin America and operations in the USA and Africa. It has 13,300 employees and 10 manufacturing plants.